Trials leave Galapagos’ SIK programme looking under the weatherGalapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound Share XTrials leave Galapagos’ SIK programme looking under the weatherhttps://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/
Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcastEpisode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as Share XGalapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/galapago-uk-michael-smyth-rna/
Gilead/Galapagos alliance hit again as IPF drug is binnedGilead and Galapagos’ much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage Share XGilead/Galapagos alliance hit again as IPF drug is binnedhttps://pharmaphorum.com/news/gilead-galapagos-alliance-hit-again-as-ipf-drug-is-binned/
NICE backs broad use for Gilead/Galapagos arthritis pill JyselecaPatients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ Share XNICE backs broad use for Gilead/Galapagos arthritis pill Jyselecahttps://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/
Gilead’s rheumatoid arthritis pill approved in JapanGilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted Share XGilead’s rheumatoid arthritis pill approved in Japanhttps://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/
Analysts question Gilead’s commitment to arthritis drug after FDA setbackThe FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage Share XAnalysts question Gilead’s commitment to arthritis drug after FDA setbackhttps://pharmaphorum.com/news/gilead-could-become/
Gilead and Galapagos shares hit as filgotinib disappointsGilead and Galapagos’ late-stage trial of their ulcerative colitis drug filgotinib has hit its target – but shares Share XGilead and Galapagos shares hit as filgotinib disappointshttps://pharmaphorum.com/news/gilead-and-galapagos-shares-hit-as-filgotinib-disappoints/
Lilly, Galapagos suspend trials as COVID-19 hits health systemsEli Lilly has said it will suspend most clinical trials for the time being in light of the Share XLilly, Galapagos suspend trials as COVID-19 hits health systemshttps://pharmaphorum.com/news/lilly-galapagos-suspend-trials-as-covid-19-hits-health-systems/
Novartis’ $100m bet on eczema drug fails as MOR106 development endsGalapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in Share XNovartis’ $100m bet on eczema drug fails as MOR106 development endshttps://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/
